Ken Keller | BiotechTV

top of page

Daiichi Sankyo's leadership comments on DESTINY-Breast06 at #ASCO24

Global Head of Oncology Ken Keller and Chief Operating Officer Hiroyuki Okuzawa describe the significance of today's data and also...

Company News

Jun 2, 2024

A deep dive into antibody-drug conjugates with Daiichi Sankyo's Ken Keller

Ken Keller describes recent advances in ADC technology, talks about the recent Merck deal, and what it was like to change breast cancer.

Company News

Jan 10, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page

Daiichi Sankyo's leadership comments on DESTINY-Breast06 at #ASCO24

A deep dive into antibody-drug conjugates with Daiichi Sankyo's Ken Keller

Follow BiotechTV

Sponsors

Sponsor Spotlight